Ptc Therapeutics, INC Form 4 insider transactions

Pierre Gravier, CFO of PTC Therapeutics, reports the acquisition of 22,500 shares of common stock and options to purchase 56,250 shares.

CEO Matthew Klein reports acquisition of stock and option grants in PTC Therapeutics.

CEO Matthew Klein of PTC Therapeutics reports the sale of 8,279 shares of common stock to cover tax obligations related to the vesting of restricted stock units (RSUs).

A PTC Therapeutics executive, Neil Gregory Almstead, executed multiple transactions involving the sale and acquisition of company stock and stock options under a pre-arranged 10b5-1 trading plan.

A PTC Therapeutics director, Jerome B. Zeldis, executed multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Christine Marie Utter, SVP and Chief Accounting Officer at PTC Therapeutics, executed multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, engaged in multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Pierre Gravier, CFO of PTC Therapeutics, sold 2,269 shares of common stock on July 16, 2024, to cover tax obligations related to the vesting of restricted stock units.

Director Jerome Zeldis exercised stock options and sold shares of PTC Therapeutics on May 22, 2024.

Director David P. Southwell transferred 1,650 shares of PTC Therapeutics common stock to an irrevocable trust on May 8, 2024.

Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, sold 175 shares of common stock on May 7, 2024, to cover tax obligations related to vesting RSUs.

PTC Therapeutics CEO Matthew B. Klein sold 3,361 shares of common stock on April 19, 2024, to cover tax obligations related to vesting RSUs.

CEO Eric Pauwels sold 787 shares of PTC Therapeutics stock on April 17, 2024, to cover tax obligations related to vesting RSUs.

PTC Therapeutics CEO Matthew Klein sold 1,307 shares of common stock on April 17, 2024, to cover tax obligations related to the vesting of restricted stock units.

Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, sold 526 shares of common stock on April 2, 2024, to cover tax obligations related to vesting RSUs.